ARS Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	97.12	89.15	0.03	1.32	5.51	17.84
Revenue Growth (YoY)	971120.00%	297063.33%	-97.72%	-76.10%	-69.13%	-
Cost of Revenue	19.37	20.56	20.27	17.12	20.27	14.07
Gross Profit	77.75	68.59	-20.24	-15.8	-14.77	3.77
Selling, General & Admin	104.82	71.68	47.28	18.66	4.69	4.23
Operating Expenses	104.82	71.68	47.28	18.66	4.69	4.23
Operating Income	-27.07	-3.08	-67.52	-34.46	-19.45	-0.47
Interest Expense	-	-	-	-	-0.8	-0.4
Currency Exchange Gain (Loss)	-	-	-	-	-	-0.2
Other Non Operating Income (Expenses)	4.47	4.12	6.01	1.12	0.01	0
EBT Excluding Unusual Items	-22.6	1.03	-61.51	-33.34	-20.24	-1.07
Gain (Loss) on Sale of Investments	7.24	7.25	6.85	-0.29	-	-
Gain (Loss) on Sale of Assets	-	-	0.3	-	-	-
Pretax Income	-15.36	8.29	-54.37	-34.68	-20.24	-1.07
Income Tax Expense	0.29	0.29	-	-	-	-
Net Income	-15.65	8	-54.37	-34.68	-20.24	-1.07
Net Income to Common	-15.65	8	-54.37	-34.68	-20.24	-1.07
Shares Outstanding (Basic)	97	97	95	40	29	20
Shares Outstanding (Diluted)	97	102	95	40	29	20
Shares Change (YoY)	1.62%	7.54%	138.30%	38.39%	42.81%	-
EPS (Basic)	-0.16	0.08	-0.57	-0.87	-0.70	-0.05
EPS (Diluted)	-0.16	0.08	-0.57	-0.87	-0.70	-0.05
Free Cash Flow	-21.06	12.99	-59.44	-40.28	-17.62	9.07
Free Cash Flow Per Share	-0.22	0.13	-0.62	-1.01	-0.61	0.45
Gross Margin	80.06%	76.94%	-	-	-268.20%	21.11%
Operating Margin	-27.87%	-3.46%	-225066.67%	-2618.54%	-353.32%	-2.63%
Profit Margin	-16.11%	8.97%	-181216.67%	-2635.41%	-367.65%	-5.97%
Free Cash Flow Margin	-21.68%	14.57%	-198136.67%	-3060.56%	-319.94%	50.86%
EBITDA	-26.72	-3	-67.45	-34.43	-19.24	-0.46
EBITDA Margin	-27.51%	-3.37%	-	-	-	-2.60%
D&A For EBITDA	0.35	0.08	0.07	0.03	0.21	0.01
EBIT	-27.07	-3.08	-67.52	-34.46	-19.45	-0.47
EBIT Margin	-27.87%	-3.46%	-	-	-	-2.63%
Effective Tax Rate	-	3.48%	-	-	-	-
Revenue as Reported	97.12	89.15	0.03	-	-	17.84

Updated May 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q